JGP study from Lukyanenko et al. (rupress.org/jgp/article/...) shows that, in the absence of full-length dysferlin, its C2A domain alone can support normal Ca2⁺ signaling and sarcolemma repair, suggesting that it could be used in gene replacement therapies. rupress.org/jgp/article/...
